Syncytial

Newark, New Castle, USA, June 21, 2023 (GLOBE NEWSWIRE) -- A recent report by Growth Plus Reports estimated the global respiratory syncytial virus (RSV) therapeutics market to be worth US$ 1.84 billion in 2022. From 2023 to 2031, market…

Respiratory Syncytial Virus (RSV) is a highly contagious and seasonal respiratory virus that mainly causes common cold symptoms in healthy adults but can cause more serious lung infections in infants, the immunocompromised and older…

Lori Solomon MONDAY, April 10, 2023 (HealthDay News) -- The respiratory syncytial virus prefusion F protein-based (RSVpreF) vaccine appears to be safe and effective for preventing RSV-associated lower…

Lori Solomon FRIDAY, April 7, 2023 (HealthDay News) – The typical timing of seasonal respiratory syncytial virus (RSV) epidemics (October to April) was disrupted during the COVID-19 pandemic, according…

Respiratory syncytial virus, more commonly known as RSV, sends thousands of children to the hospital every year in the U.S. But during September and October 2022, health professionals across the country have watched an unprecedented…

An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could provide an effective treatment against RSV…

A new study found that nearly one in ten of all deceased infants under 6 months old were infected with Respiratory Syncytial Virus (RSV). Two-thirds of infant fatalities from RSV occurred in the community and would have been excluded from…

SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir (AK0529) for the treatment of respiratory…

Nearly everyone gets infected with respiratory syncytial virus (RSV) repeatedly over the course of a lifetime, starting in childhood. Most times, people fight off the virus handily and only end up with a mild cold. But some people -- most…

Los Angeles, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Respiratory Syncytial Virus Infection Pipeline: Insights into Clinical Trial Landscape, Key Pharma Players, Emerging Therapies with Novel MoAs, and Dynamics Shaping the Pipeline…